Eli Lilly and Company

Lilly Industries, Inc.

University of East Anglia

Other

Lilly, Sa

Stephen Richard Baker

Concepcion Pedregal Tercero

James E Audia

Jesus Ezquerra Carrera

Carlos Lamas Peteira

Alec Todd

William J Ross

William B Jamieson

Jason Scott Sawyer

Nicholas J Bach

Jeremy Gilmore

John Goldsworthy

Russell Andrew Lewthwaite

Alexander McKillop

George Richard Stephenson

Dennis Michael Zimmerman

Paul Leslie Ornstein

Richard L Simon

Hamideh Zarrinmayeh

Barry P Clark

Edward C R Smith

Macklin Brian Arnold

Ken Matsumoto

Ana Maria Escribano

Thomas John Bleisch

Buddy Eugene Cantrell

David Bleakman

Tracey E McKennon

Michael William Urquhart

James Allen Monn

John Richard Harris

Terry D Lindstrom

Joseph P Tizzano

Carlos Lamas-Peteira

Lourdes Prieto

Almudena Rubio Esteban

Christopher David Beadle

Michael William John Urquhart

William B Jamieson, Deceased

The present invention provides novel mGlu2/3 agonists of the formula wherein R, R, and Rare as defined herein, for use in the treatment of neurological or psychiatric disorders.

MGlu 2/3 agonists

The present invention relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.

Sulphonamide derivatives

Use of compounds of the formula (I) where A, E, R, R, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.

Naphtalene derivatives and their pharmaceutical use

This invention relates to a method of making N-benzyl indoles, and to intermediates for use in the method, and to certain substantially optically pure N-benzyl indoles obtained by the method.

Process for preparing N-benzyl indoles

Process for preparing n-benzyl indoles

Pharmaceutical compounds of the formula ##STR1## in which n is 0, 1 or 2 and m is 1 or 2, R.sup.1 is hydrogen, C.sub.1-10 alkyl, C.sub.2-10 alkenyl, C.sub.2-10 alkynyl, phenyl, naphthyl, C.sub.1-10 alkyl-phenyl, C.sub.2-10 alkenyl-phenyl or C.sub.2-10 alkynyl-phenyl, said phenyl and naphthyl groups being optionally substituted, R.sup.2 is hydrogen or a protecting group, and Q is an acidic group; or a salt or ester thereof.

Pharmaceutical compounds

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

Aminoalkyl-indoles

A pharmaceutical compound of the formula: ##STR1## in which R.sup.1 is hydrogen, hydroxy or C.sub.1-6 alkoxy, R.sup.2 is hydrogen, carboxy, tetrazolyl, --SO.sub.2 H, --SO.sub.3 H, --OSO.sub.3 H, --CONHOH, or --P(OH)OR', --PO(OH)OR', --OP(OH)OR' or --OPO(OH)OR' where R' is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or aryl C.sub.1-6 alkyl,

Phenylglycine derivatives useful for treating disorders of the central

Tetrahydro-Beta-Carbolines

Tetrahydro-beta-carbolines

A process for producing a compound of the formu5la ##STR1## comprising the step of reacting a compound of the formula ##STR2## with a compound of the formula ##STR3## to form a compound of the formula ##STR4## wherein R.sup.2a is selected from the groups recited above for R.sup.2, or R.sup.2a --X-- is a protected hydroxyl group, and Z is a group of formula --Y--R.sub.5 recited above, or a group that can be converted into a group of said formula --Y--R.sup.5. Intermediates of formula IV and composition containing substantially optically pure enantiomers of Formula (I) are included within the scope of the invention.

Tetrahydro-beta carbolines

Growing community of inventors

Yateley, United Kingdom

Stephen Richard Baker